Eli Lilly’s Stock Hinges on Upcoming FDA Decision for Oral Weight-Loss Drug

Pharmaceutical giant Eli Lilly is approaching a pivotal regulatory milestone. The U.S. Food and Drug Administration (FDA) is expected to announce its verdict on Orforglipron, an oral weight-loss medication, by April 10. This decision could unlock a multi-billion dollar market and provide a fresh catalyst for the company’s shares, which have recently faced headwinds despite strong commercial performance.

Investor sentiment has turned cautious, with the stock declining approximately 15.4% since the start of the year to trade near 780 euros. This pressure underscores how much future growth is already reflected in the share price and highlights the market’s sensitivity to pipeline developments. Even a minor scheduling shift by the FDA, moving the decision date from late March to April 10, was enough to unsettle investors, despite such adjustments being routine in the industry.

Shifting the Competitive Landscape

The current market for obesity treatments is dominated by injectable drugs. Orforglipron, taken as a pill, promises to lower the barrier to treatment for many patients by offering a more convenient alternative. It holds a potential practical advantage over a rival oral therapy from Novo Nordisk, as it does not require patients to follow strict morning fasting rules. From a commercial perspective, the tablet form also presents Eli Lilly with tangible economic benefits, including lower production and storage costs. Analysts at Evaluate project the drug could achieve annual sales of $11.8 billion by 2032.

Clinical data provides a foundation for this optimism. In the ACHIEVE-3 study, Orforglipron demonstrated superior weight reduction compared to Novo Nordisk’s competing product. However, the trial also reported a higher incidence of gastrointestinal side effects, leading to increased discontinuation rates. The FDA’s review will scrutinize these tolerability concerns closely. Competition is intensifying, as evidenced by Structure Therapeutics releasing promising Phase 2 data for its own oral candidate in mid-March, which may offer a better side-effect profile.

Should investors sell immediately? Or is it worth buying Eli Lilly?

Upcoming Catalysts and Analyst Outlook

Market experts at Morgan Stanley maintain a buy rating on Eli Lilly’s stock. They point to a growing trend among U.S. employers to cover at least part of the cost for anti-obesity medications. Nevertheless, a pattern is emerging where insurers and employers are implementing stricter reimbursement criteria, such as specific BMI thresholds or mandatory participation in lifestyle programs.

Beyond the imminent April FDA decision, the next significant catalyst is already in view. In June, at the American Diabetes Association congress, Eli Lilly is scheduled to present detailed Phase 3 results for Retatrutide, another promising drug candidate. These findings will be crucial in determining whether the company can defend its technological leadership in the obesity market against an expanding field of competitors.

The recent quarterly performance of blockbuster drugs Mounjaro and Zepbound, which saw substantial revenue increases, has been overshadowed by the market’s focus on the future pipeline. The approval of Orforglipron represents a key opportunity for Eli Lilly to reignite growth momentum and capitalize on the vast potential of the oral weight-loss segment.